<DOC>
	<DOCNO>NCT00102973</DOCNO>
	<brief_summary>The purpose research study determine TLK286 give combination carboplatin effective liposomal doxorubicin treat woman recurrent ovarian epithelial cancer , fallopian tube cancer , primary peritoneal cancer , refractory resistant platinum chemotherapy .</brief_summary>
	<brief_title>TLK286 ( Telcyta ) Combination With Carboplatin ( Paraplatin ) Versus Doxil Platinum Refractory Resistant Ovarian Cancer</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>Are woman 18 year age old Have histologically cytologically confirm epithelial cancer ovary fallopian tube , primary peritoneal cancer Have platinum refractory resistant cancer Measurable disease accord radiographic RECIST criterion document tumor progression Had treatment firstline chemotherapy platinumbased regimen ( carboplatin cisplatin ) Have clinically significant cardiac disease Have sign intestinal obstruction interfere nutrition time study entry Are pregnant lactating Had prior treatment liposomal doxorubicin ovarian cancer Had prior treatment TLK286</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2006</verification_date>
	<keyword>Ovary</keyword>
</DOC>